Immunohistochemistry for cyclin D3 is a promising marker as it is reported to be expressed in approximately 70% of SDRPLs and not in other splenic B-cell lymphomas, but the current data are still limited [48, 49]. Here, CCND3 is linked to B-cell non-Hodgkin lymphoma.